Gastroenterology
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.
From the Journals
Pediatric Crohn’s disease: Adalimumab plus methotrexate offers strong benefit
“We believe these results are practice-changing.”
Latest News
Children ate more fruits and vegetables during longer meals: Study
Modest extension of family mealtimes significantly increased children’s fruit and vegetable consumption.
From the Journals
Likely cause of mysterious hepatitis outbreak in children identified
The study’s key messages for parents and health care providers “are awareness and reassurance,” Dr. Balistreri said in an interview.
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
Commentary
Celebrity death finally solved – with locks of hair
Case: A 56-year-old musician presents with diffuse abdominal pain, cramping, and jaundice. His medical history is notable for years of diffuse...
Conference Coverage
Mental health risks higher among young people with IBD
“Anxiety and depression will not be a surprise to most of us. But we also saw changes for eating disorders, PTSD, and sleep changes.”
Conference Coverage
Pediatric IBD patients wrestle with lingering gut pain
Chronic pain in children and adolescents with IBD is not linked to disease activity, nonetheless it impacts emotional wellbeing which suggests...
From the Journals
Does CRC risk in IBD extend to close family members?
Extra screening for CRC may not be needed for children, siblings, or parents of those with IBD, new study findings suggest.
From the Journals
Colorectal cancer incidence doubled in younger adults
Diagnoses in people younger than 55 years doubled from 1995 to 2019.